January 27, 2025 |
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Construction Partners, Inc. (“Construction Partners” or “the Company”) (NASDAQ: ROAD). Investors who purchased Construction Partners securities are encouraged to obtain additional information and assist the investigation. The investigation concerns whether Construction… read more
January 24, 2025 |
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Ford Motor Company (“Ford” or “the Company”) (NYSE: F). Investors who purchased Ford securities prior to October 28, 2021, and continue to hold to the present, are encouraged to obtain additional… read more
January 23, 2025 |
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Electronic Arts Inc. (“EA” or “the Company”) (NASDAQ: EA). Investors who purchased EA securities are encouraged to obtain additional information and assist the investigation. The investigation concerns whether EA has violated… read more
January 22, 2025 |
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Zeta Global Holdings Corp. (“Zeta” or “the Company”) (NYSE: ZETA). Investors who purchased Zeta securities prior to February 27, 2024, and continue to hold to the present, are encouraged to obtain… read more
January 21, 2025 |
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of JinkoSolar Holding Co., Ltd. (“JinkoSolar” or “the Company”) (NYSE: JKS). Investors who purchased JinkoSolar securities are encouraged to obtain additional information and assist the investigation. The investigation concerns whether JinkoSolar has… read more
January 16, 2025 |
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Keros Therapeutics, Inc. (“Keros” or “the Company”) (NASDAQ: KROS). Investors who purchased Keros securities are encouraged to obtain additional information and assist the investigation. The investigation concerns whether Keros has violated… read more
January 14, 2025 |
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of XBiotech Inc. (“XBiotech” or “the Company”) (NASDAQ: XBIT). Investors who purchased XBiotech securities are encouraged to obtain additional information and assist the investigation. The investigation concerns whether XBiotech has violated federal… read more
January 13, 2025 |
Bronstein, Gewirtz & Grossman, LLC is investigating the merger between Enfusion, Inc. (“Enfusion”) (NYSE: ENFN) and Clearwater Analytics. Investors who purchased Enfusion and continue to hold to the present are encouraged to obtain additional information and assist the investigation. Investigation Details The investigation concerns whether… read more
January 10, 2025 |
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Johnson & Johnson (“J&J” or “the Company”) (NYSE: JNJ). Investors who purchased J&J securities are encouraged to obtain additional information and assist the investigation. The investigation concerns whether J&J has violated… read more
January 9, 2025 |
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of MicroCloud Hologram Inc. (“MicroCloud” or “the Company”) (NASDAQ: HOLO). Investors who purchased MicroCloud securities are encouraged to obtain additional information and assist the investigation. The investigation concerns whether MicroCloud has violated… read more
January 9, 2025 |
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Rigetti Computing, Inc. (“Rigetti” or “the Company”) (NASDAQ: RGTI). Investors who purchased Rigetti securities are encouraged to obtain additional information and assist the investigation. The investigation concerns whether Rigetti has violated… read more
January 6, 2025 |
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Apellis Pharmaceuticals, Inc. (“Apellis” or “the Company”) (NASDAQ: APLS). Investors who purchased Apellis securities prior to January 28, 2021, and continue to hold to the present, are encouraged to obtain additional… read more
January 3, 2025 |
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Tungray Technologies Inc (“Tungray” or “the Company”) (NASDAQ: TRSG). Investors who purchased Tungray securities are encouraged to obtain additional information and assist the investigation. The investigation concerns whether Tungray has violated… read more
January 2, 2025 |
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Vail Resorts, Inc. (“Vail Resorts” or “the Company”) (NYSE: MTN). Investors who purchased Vail Resorts securities are encouraged to obtain additional information and assist the investigation. The investigation concerns whether Vail… read more
December 31, 2024 |
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Sangamo Therapeutics, Inc. (“Sangamo” or “the Company”) (NASDAQ: SGMO). Investors who purchased Sangamo securities are encouraged to obtain additional information and assist the investigation. The investigation concerns whether Sangamo has violated… read more
December 30, 2024 |
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Paragon 28, Inc. (“Paragon 28” or “the Company”) (NYSE: FNA). Investors who purchased Paragon 28 securities prior to May 5, 2023, and continue to hold to the present, are encouraged to… read more
December 30, 2024 |
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Sage Therapeutics, Inc. (“Sage” or “the Company”) (NASDAQ: SAGE). Investors who purchased Sage securities prior to April 12, 2021, and continue to hold to the present, are encouraged to obtain additional… read more
December 30, 2024 |
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Sonder Holdings Inc. (“Sonder” or “the Company”) (NASDAQ: SOND). Investors who purchased Sonder securities prior to March 16, 2023, and continue to hold to the present, are encouraged to obtain additional… read more
December 30, 2024 |
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Spire Global, Inc. (“Spire” or “the Company”) (NYSE: SPIR). Investors who purchased Spire securities prior to May 11, 2022, and continue to hold to the present, are encouraged to obtain additional… read more
December 30, 2024 |
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Sprout Social, Inc. (“Sprout” or “the Company”) (NASDAQ: SPT). Investors who purchased Sprout securities prior to November 3, 2021, and continue to hold to the present, are encouraged to obtain additional… read more
December 30, 2024 |
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Arbor Realty Trust (“Arbor Realty” or “the Company”) (NYSE: ABR). Investors who purchased Arbor Realty securities prior to May 7, 2021, and continue to hold to the present, are encouraged to… read more
December 30, 2024 |
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Allarity Therapeutics, Inc. (“Allarity” or “the Company”) (NASDAQ: ALLR). Investors who purchased Allarity securities prior to May 17, 2022, and continue to hold to the present, are encouraged to obtain additional… read more
December 30, 2024 |
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of General Motors Company (“General Motors” or “the Company”) (NYSE: GM). Investors who purchased General Motors securities prior to February 2, 2022, and continue to hold to the present, are encouraged to… read more
December 24, 2024 |
Bronstein, Gewirtz & Grossman, LLC is investigating the merger between NeueHealth, Inc. (“NeueHealth”) (NYSE: NEUE) and New Enterprise Associates (“NEA”). Investors who purchased NeueHealth and continue to hold to the present are encouraged to obtain additional information and assist the investigation. Investigation Details The investigation… read more
December 23, 2024 |
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Walmart Inc. (“Walmart” or “the Company”) (NYSE: WMT). Investors who purchased Walmart securities are encouraged to obtain additional information and assist the investigation. The investigation concerns whether Walmart has violated federal… read more
December 20, 2024 |
Bronstein, Gewirtz & Grossman, LLC is investigating the merger between Liberty TripAdvisor Holdings, Inc. (“Liberty TripAdvisor”) (OTCMKTS: LTRPA) and TripAdvisor. Investors who purchased Liberty TripAdvisor and continue to hold to the present are encouraged to obtain additional information and assist the investigation. Investigation Details The… read more
December 18, 2024 |
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Elanco Animal Health Incorporated (“Elanco” or “the Company”) (NYSE: ELAN). Investors who purchased Elanco securities prior to November 7, 2023, and continue to hold to the present, are encouraged to obtain… read more
December 18, 2024 |
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Cummins Inc. (“Cummins” or “the Company”) (NYSE: CMI). Investors who purchased Cummins securities prior to April 30, 2019, and continue to hold to the present, are encouraged to obtain additional information… read more
December 17, 2024 |
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Enovix Corporation (“Enovix” or “the Company”) (NASDAQ: ENVX). Investors who purchased Enovix securities are encouraged to obtain additional information and assist the investigation. The investigation concerns whether Enovix has violated federal… read more
December 12, 2024 |
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Verve Therapeutics, Inc. (“Verve” or “the Company”) (NASDAQ: VERV). Investors who purchased Verve securities prior to August 9, 2022, and continue to hold to the present, are encouraged to obtain additional… read more